Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

27. April 2016 12:53 ET | Quelle: International Society for Heart and Lung Transplantation

Cell Therapy and Tissue Engineering Hot Topic at 36th Annual International Society of Heart & Lung Transplantation Meeting and Scientific Sessions

WASHINGTON, April 27, 2016 (GLOBE NEWSWIRE) -- Today at the 36th Annual International Society for Heart and Lung Transplantation (ISHLT) Meeting & Scientific Sessions, researchers from Cedars-Sinai...
22. April 2016 12:30 ET | Quelle: Adaptimmune Therapeutics plc

Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day

PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
11. April 2016 11:35 ET | Quelle: Genetics Policy Institute

Regenerative Medicine Foundation to Highlight Need for New Regulatory Pathway for Cell Therapies at April 12th Event

WASHINGTON, April 11, 2016 (GLOBE NEWSWIRE) -- Tomorrow, the Regenerative Medicine Foundation (RMF) will co-host an event with the Bipartisan Policy Center (BPC) on advancing the availability and use...
07. April 2016 09:05 ET | Quelle: The Leona M. and Harry B. Helmsley Charitable Trust

Helmsley Charitable Trust Awards $2.1 Million to Penn, Stanford and Seattle Children's Research Institute to Explore Cell-Based Therapies for Type 1 Diabetes

NEW YORK, April 7, 2016 (GLOBE NEWSWIRE) -- The Type 1 Diabetes (T1D) Program of The Leona M. and Harry B. Helmsley Charitable Trust has announced $2.1 million in grants to support research toward the...
07. April 2016 09:02 ET | Quelle: Adaptimmune Therapeutics plc

Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer

PHILADELPHIA and OXFORD, United Kingdom, April 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
30. März 2016 07:40 ET | Quelle: Adaptimmune Therapeutics plc

U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today...
17. März 2016 07:56 ET | Quelle: Adaptimmune Therapeutics plc

Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015

PHILADELPHIA and OXFORD, United Kingdom, March 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to...
11. Februar 2016 06:00 ET | Quelle: Cesca Therapeutics Inc.

Cesca Therapeutics to Announce Second Quarter Fiscal 2016 Results and Provide a Status Update to Investors on February 16, 2016

RANCHO CORDOVA, Calif., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report...
02. Februar 2016 08:20 ET | Quelle: Adaptimmune Therapeutics plc

Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)

PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will...
02. Februar 2016 08:16 ET | Quelle: Adaptimmune Therapeutics plc

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trialsCreates opportunity for up to eight combination studies LONDON, PHILADELPHIA...

Vorherige Seite